¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ [8/6] WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ (COVID-19 Global Epidemiological Update )
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

 

 

[8/6]

WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ

(COVID-19 Global Epidemiological Update )

 


 

 

COVID-19 ±¹Á¦ ÇöȲ(Global Overview)

 

-2021³â 8¿ù Àü¼¼°è ¾à 2¾ï¸íÀÌ»ó Äڷγª¹ÙÀÌ·¯½º °¨¿° »ç·Ê º¸°í -

 

 

Àü ¼¼°èÀûÀ¸·Î Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÌ Áö¼ÓÀûÀ¸·Î È®»êµÇ°í ÀÖ´Ù. 2021³â 8¿ù 4ÀÏ ¿ÀÈÄ 6½Ã 44ºÐ CEST ±âÁØÀ¸·Î WHO¿¡ º¸°íµÈ Äڷγª¹ÙÀÌ·¯½º °¨¿°Àº 4,244,541¸íÀÇ »ç¸ÁÀÚ¸¦ Æ÷ÇÔÇÏ¿© 199,466,211¸íÀÇ COVID-19 ´©Àû È®ÁøÀÚ¸¦ º¸°íÇß´Ù.  Johns Hopkins ´ëÇÐ ¿¬±¸¼Ò ÀÚ·á¿¡ ÀÇÇϸé Àü¼¼°èÀûÀ¸·Î COVID-19 ´©Àû È®ÁøÀÚ¼ö´Â 200,792,438¸í(8¿ù 6ÀÏ ±âÁØ)ÀÌ°í, »ç¸ÁÀÚ´Â 4,265,797¸íÀ¸·Î º¸°íµÈ´Ù.  Àü¼¼°è ¹é½ÅÁ¢Á¾ ÇöȲÀº Áß±¹ÀÌ 1,726,223,000 Á¢Á¾À¸·Î °¡Àå ³ô¾Ò°í ±× µÚ¸¦ À̾î Àεµ 489,342,295°Ç, ¹Ì±¹ 347,956,640 °ÇÀ¸·Î ³ªÅ¸³µ´Ù(±×¸² 1).

 

 

 

±×¸²1 . ±Û·Î¹ú COVID-19 ¹é½ÅÁ¢Á¾ÇöȲ(Johns Hopkins ´ëÇבּ¸¼Ò ÀÚ·á. 2021³â 8¿ù 6ÀÏ ±âÁØ)



 

Äڷγª¹ÙÀÌ·¯½º °¨¿°Àº Áö³­ ÁÖ¿Í ºñ±³ÇÏ¿© 548,167¸íÀÌ ½Å±Ô È®ÁøµÇ¾ú½À´Ï´Ù. ÀÌÁß ºÏ¹Ì¿¡¼­ 142,737¸íÀ¸·Î °¡Àå ¸¹¾ÒÀ¸¸ç, À¯·´ 141,528¸í, µ¿³²¾Æ½Ã¾Æ 119,588¸íÀÇ ¼øÀ¸·Î È®ÁøÀÚ°¡ ¹ß»ýÇÏ¿´½À´Ï´Ù. ±¹°¡º° ÇöȲÀº ¾Æ·¡ ±×¸² 1À» Âü°íÇÏ¸é µË´Ï´Ù.

 

±×¸² 2. COVID-19 ±Û·Î¹ú È®Áø»ç·Ê ¹× »ç¸ÁÀÚ ÃßÀÌ( WHO Region, as of 3 August 2021)

 

±×¸² 3. ±¹°¡º° Äڷγª19°¨¿° ȯÀÚ ÇöȲ(WHO CEST, 4 August ±âÁØ)

 

Áö³­ ÁÖ(2021³â 7¿ù 26ÀϺÎÅÍ 8¿ù 1ÀϱîÁö)¿¡ 400¸¸ °Ç ÀÌ»óÀÇ »ç·Ê°¡ º¸°íµÇ¾î ÇÑ´Þ ÀÌ»ó, Àü ¼¼°èÀûÀ¸·Î »õ·Î¿î »ç·Ê°¡ Áõ°¡Ãß¼¼¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡ Ãß¼¼´Â ÁÖ·Î 37% ¹× 33% Áõ°¡¸¦ º¸°íÇÑ µ¿ºÎ ÁöÁßÇØ ¹× ¼­ÅÂÆò¾ç Áö¿ªÀÇ »ó´çÇÑ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. µ¿³² ¾Æ½Ã¾Æ Áö¿ªÀº 9% Áõ°¡¸¦ º¸°íÇÑ ¹Ý¸é(±×¸² 1); ´Ù¸¥ ¼¼ Áö¿ªÀº ºñ½ÁÇÑ ÁÖ°£ »ç·Ê ¹ß»ý·üÀ» º¸°íÇ߰ųª ÀÌÀü ÁÖ¿¡ ºñÇØ ¾à°£ °¨¼ÒÇß½À´Ï´Ù. 

 

±×¸² 4. ±Û·Î¹ú COVID-19 ´©ÀûÈ®ÁøÀÚ ¹× »ç¸Á·ü ÇöȲ(WHO CEST, 4 August ±âÁØ)



 

Àü¹ÝÀûÀ¸·Î À̹ø ÁÖ Äڷγª ¹ÙÀÌ·¯½º·Î ÀÎÇØ º¸°íµÈ »ç¸ÁÀÚ ¼ö´Â ÀÌÀü¿¡ ºñÇØ 8% °¨¼ÒÇß°í, ÀÏÁÖÀÏ µ¿¾È 64,000¸í ÀÌ»óÀÇ »ç¸ÁÀÚ°¡ º¸°í µÇ¾ú½À´Ï´Ù. ´Ù¸¸ ¼­ÅÂÆò¾ç°ú µ¿ÁöÁßÇØ Áö¿ªÀº ÀüÁÖ¿¡ ºñ±³ÇÏ¿© ½Å±Ô »ç¸ÁÀÚ°¡ 48%, 31% ±ÞÁõÇÑ °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ´Ù¸¥ 4°³ Áö¿ªÀº ÀÌÀü°ú À¯»çÇÑ ÁÖ°£ »ç¸ÁÀÚ ¼ö¸¦ º¸°íÇß½À´Ï´Ù(±×¸² 1). Àü ¼¼°èÀûÀ¸·Î º¸°íµÈ »ç·ÊÀÇ ¼ö´Â ÇöÀç °ÅÀÇ 1¾ï 9,700¸¸ ¸íÀÌ¸ç ´©Àû »ç¸ÁÀÚ ¼ö´Â 420¸¸ ¸íÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼°¡ °è¼ÓµÈ´Ù¸é Àü ¼¼°èÀûÀ¸·Î º¸°íµÇ´Â ´©Àû »ç·Ê ¼ö´Â ´ÙÀ½ ÁÖ±îÁö 2¾ï ¸íÀ» ³ÑÀ» °ÍÀ¸·Î ¿¹»óÇÏ°í ÀÖ½À´Ï´Ù.



 

±×¸² 5. WHO Áö¿ªº° COVID-19 ¹ß»ýÀÚ ÇöȲ(WHO CEST, 4 August ±âÁØ)




 

¾ËÆÄ, º£Å¸, µ¨Å¸ º¯ÀÌ ¹ÙÀÌ·¯½º Ãß¼¼

 

Àü ¼¼°èÀûÀ¸·Î ¾ËÆÄ º¯ÀÌÀÇ »ç·Ê´Â 182°³ ±¹°¡¿¡¼­ º¸°íµÈ ¹Ý¸é, 132°³±¹(1°³ »õ·Î¿î ±¹°¡)¿¡¼­ º£Å¸ º¯ÀÌ »ç·Ê°¡ º¸°íµÇ¾ú½À´Ï´Ù. 81°³ ±¹°¡(1°³ ½Å±Ô ±¹°¡)¿¡¼­ °¨¸¶ º¯ÀÌ°¡ º¸°íµÇ¾ú½À´Ï´Ù. µ¨Å¸ º¯ÀÌÀÇ °æ¿ì, 135°³±¹(3°³ ½Å±Ô ±¹°¡)ÀÌ º¸°íµÇ¾ú½À´Ï´Ù. ÇöÀç±îÁö ¾ËÆĺ¯ÀÌ¿Í µ¨Å¸º¯ÀÌ ¹ÙÀÌ·¯½º°¡ ÃÑ 317°³±¹¿¡¼­ °¡Àå ³ôÀº ¹ÙÀÌ·¯½º·Î ³ªÅ¸³µ½À´Ï´Ù. 

 

±¹Á¦Àû º¯À̹ÙÀÌ·¯½º È®»ê°ú °ü·ÃÇÏ¿© 7¿ù¿¡ º¸°íµÈ ¾ËÆÄ º¯ÀÌÀÇ »ç·Ê´Â 173°³ ±¹°¡, º£Å¸º¯ÀÌ 122°³ ±¹°¡(3°³ »õ·Î¿î ±¹°¡), µ¨Å¸º¯ÀÌ 104°³ ±¹°¡(7°³ »õ·Î¿î ±¹°¡), °¨¸¶º¯ÀÌ 74°³±¹°¡(2°³ »õ·Î¿î ±¹°¡)¿Í ºñ±³ÇÏ¿©(±×¸² 4), º¯À̹ÙÀÌ·¯½º´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Ãß¼¼¿¡ ÀÖ½À´Ï´Ù. À̹ø ¹öÀü¿¡¼­´Â VOCÀÇ Ç¥ÇöÇü Ư¼º(ÀüÆļº, Áúº´½É°¢µµ, Àç°¨¿° À§Çè, Áø´Ü ¹× ¹é½Å È¿´É ¿µÇâ)¿¡ °ü·ÃµÈ »õ·Î¿î ¾÷µ¥ÀÌÆ®, Áö¸®Àû ºÐÆ÷¿¡ ´ëÇÑ ¾÷µ¥ÀÌÆ® ¹×  º¯ÀÌ¿¡ ´ëÇØ ÃÊÁ¡À» µÎ¾ú´Ù. VOCs ¹× º¯ÀÌ ºÐ·ù, ¸ð´ÏÅ͸µÁßÀÎ ¾Æ¹Ì³ë»ê º¯È­ ¹× ±âŸ º¯ÀÌ ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ¾÷µ¥ÀÌÆ® ¹× VOIÀÇ Á¤ÀǸ¦ Æ÷ÇÔÇÕ´Ï´Ù. 

 

º¯ÀÌ ¹ÙÀÌ·¯½º ¾÷µ¥ÀÌÆ®(Special Focus: Update on SARS-CoV-2 Variants of Interest and Variants of Concern)

 

¿ì·Á º¯ÀÌ ¹ÙÀÌ·¯½º(Variants of Concern, VOC) ÇöȲ

±×¸² 6. WHO ¿ì·Á º¯ÀÌ ¹ÙÀÌ·¯½ºÁ¾ ¹ß°ß ÇöȲ



 

WHO°¡ Á¤ÀÇÇÏ´Â ¿ì·Á¹ÙÀÌ·¯½º(VOI)¶õ?

 

WHO´Â SARS-CoV-2 º¯ÀÌ, ƯÈ÷ VOI¿¡ ´ëÇÑ Á¤ÀÇ(Definition)¸¦ ¼¼¿ì±â À§ÇØ ¹ÙÀÌ·¯½º °£ ºñ±³ Æò°¡¸¦ ÅëÇÏ¿© Àü ¼¼°è °øÁߺ¸°Ç¿¡ Á߿伺°ú ½É°¢¼º Á¤µµ¸¦ Æò°¡ÇÏ°í, ¾Æ·¡ º¯È­ Áß Çϳª ÀÌ»ó°ú °ü·ÃÀÌ ÀÖ´Â °ÍÀ¸·Î VOI¸¦ Á¤ÀÇÇÕ´Ï´Ù.

 

-COVID-19 ¿ªÇÐÀÇ °¨¿°¼º Áõ°¡ ¶Ç´Â À¯ÇØÇÑ º¯È­; ¶Ç´Â

-µ¶¼ºÀÇ Áõ°¡ ¶Ç´Â ÀÓ»óÁúȯ ¹ßÇöÀÇ º¯È­; ¶Ç´Â

-°øÁß º¸°Ç ¹× »çȸÀû Á¶Ä¡ ¶Ç´Â ÀÌ¿ë °¡´ÉÇÑ Áø´Ü, ¹é½Å, Ä¡·áÁ¦ÀÇ È¿°ú °¨¼Ò.





 

Ç¥ 1. WHO Áö¿ªº° COVID-19 ½Å±Ô È®ÁøÀÚ ¹× »ç¸ÁÀÚ ÇöȲ(WHO Region, as of 3 August 2021) 

*Percent change in the number of newly confirmed cases/deaths in the past seven days, compared to seven days prior. **See Annex: Data, table and figure notes (Source: WHO Weekly COVID-19 Update as of 3 Aughst 2021)






 

±×¸² 7. COVID-19 È®ÁøÀÚ: Àα¸ 10¸¸¸í´ç º¸°í( by countries, territories and areas, , 26 July- 1 August 2021, WHO)



 

¼¼°èº¸°Ç±â±¸(WHO)´Â ±¹°¡ ´ç±¹, ±â°ü ¹× ¿¬±¸ÀÚµé°ú Çù·ÂÇÏ¿© SARS-CoV-2ÀÇ º¯ÀÌ ¹ÙÀÌ·¯½º°¡ °¨¿°È®»ê, Áúº´ ½É°¢¼ºÀ» º¯°æÇÏ´ÂÁö¸¦ ¸ð´ÏÅ͸µÇÏ°í ±¹°¡µéÀÇ °øÁߺ¸°ÇÁ¤Ã¥ ¹× »çȸÁ¶Ä¡ (PHSM)¿¡¼­ ¹é½Å, Ä¡·á, Áø´Ü È¿°ú¿¡ ¿µÇâÀ» ¹ÌÄ¡´ÂÁö Á¤±âÀûÀ¸·Î Æò°¡ÇÏ°í ÀÖ´Ù. 

 

±×¸² 8. COVID-19 »ç¸ÁÀÚ: Àα¸ 10¸¸¸í´ç º¸°í( by countries, territories and areas, , 26 July- 1 August 2021, WHO)




 

 ±¹³» COVID-19 ¹ß»ý ¹× ¹é½ÅÁ¢Á¾ ÇöȲ

 

Á߾ӹ濪´ëÃ¥º»ºÎ´Â 8¿ù 6ÀϱâÁØÀ¸·Î, ±¹³» ¹ß»ý ½Å±Ô È®ÁøÀÚ´Â 1,640¸í, ÇØ¿ÜÀ¯ÀÔ »ç·Ê´Â 64¸íÀÌ È®ÀεǾî ÃÑ ´©Àû È®ÁøÀÚ ¼ö´Â 207,406¸í(ÇØ¿ÜÀ¯ÀÔ 12,254¸í)À̶ó°í ¹àÇû´Ù. ÀÇ½É½Å°í °Ë»çÀÚ ¼ö´Â 43,216¸í, ¼öµµ±Ç Àӽü±º°°Ë»ç¼Ò °Ë»ç °Ç¼ö´Â 74,720°Ç(È®ÁøÀÚ 321¸í), ºñ¼öµµ±Ç Àӽü±º°°Ë»ç¼Ò °Ë»ç °Ç¼ö´Â 18,426°Ç(È®ÁøÀÚ 66¸í)À¸·Î ÃÑ °Ë»ç °Ç¼ö´Â 136,362°Ç, ½Å±Ô È®ÁøÀÚ´Â ÃÑ 1,704¸íÀÌ´Ù. ½Å±Ô °Ý¸® ÇØÁ¦ÀÚ´Â 1,333¸íÀ¸·Î ÃÑ 182,052¸í(87.78%)ÀÌ °Ý¸® ÇØÁ¦µÇ¾î, ÇöÀç 23,241¸íÀÌ °Ý¸® ÁßÀÌ´Ù. À§ÁßÁõ ȯÀÚ´Â 376¸í, »ç¸ÁÀÚ´Â 4¸íÀ¸·Î ´©Àû »ç¸ÁÀÚ´Â 2,113¸í·Î ³ªÅ¸³µÀ¸¸ç Ä¡¸í·üÀº 1.02% ÀÌ´Ù.



 

Ç¥ 2. ±¹³» Äڷγª-19 ½Å±Ô È®ÁøÀÚ Áö¿ªº° ÇöȲ(8¿ù6ÀÏ ±âÁØ)

 

±¹³» Äڷγª19 ¿¹¹æÁ¢Á¾ ´ëÀÀÃßÁø´ÜÀº ¹é½ÅÁ¢Á¾ ÇöȲÀ» 8¿ù6ÀÏ ±âÁØÀ¸·Î 1Â÷ Á¢Á¾Àº 191,478¸íÀ¸·Î ÃÑ 20,529,566¸íÀÌ 1Â÷ Á¢Á¾À» ¹Þ¾Ò°í, ÀÌ Áß 126,304¸íÀÌ Á¢Á¾À» ¿Ï·áÇÏ¿© ÃÑ 7,526,904¸íÀÌ Á¢Á¾À» ¿Ï·áÇÏ¿´´Ù°í ¹àÇû´Ù.

 

Ç¥ 3. ±¹³» Äڷγª-19 ¹é½Åº° Á¢Á¾ ÇöȲ(8¿ù 6ÀÏ ±âÁØ)

Ç¥ 4. ¹é½Å À¯Çüº° Á¢Á¾ ÇöȲ(8¿ù 6ÀÏ ±âÁØ)





 

[ÃֽŠ¿¬±¸µ¿Çâ] Coronavirus 2019 (COVID-19)] Highlights

 

¸ð´õ³ª ¹é½Å È¿°ú  90%ÀÌ»ó, 6°³¿ù Áö¼Ó¼º,  µ¨Å¸º¯ÀÌ ¿¹¹æÈ¿°ú

(Moderna COVID-19 Vaccine Overview and Safety)



 

Moderna ¹é½ÅÀº ¼¼Æ÷¿¡ ¾à°£ÀÇ À¯Àü Äڵ带 Àü´ÞÇÏ´Â ±â¼úÀÎ mRNA ¶Ç´Â ¸Þ½ÅÀú RNA¸¦ »ç¿ëÇÏ¿© »ý¼ºµÈ´Ù. ÃÖ±Ù CDC ¿¬±¸¿¡ µû¸£¸é ½ÇÁ¦ ȯ°æ¿¡¼­ ¿ÏÀü ¿¹¹æÁ¢Á¾(µÎ ¹ø° Á¢Á¾ ÈÄ ÃÖ¼Ò 14ÀÏ) ½Ã ¹é½ÅÀÇ È¿°ú°¡ 90% ÀÌ»óÀÎ °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç ¿¹¹æÈ¿°ú´Â Á¢Á¾ ¿Ï·á ÈÄ ¾à 6°³¿ù Áö¼ÓµÇ´Â °ÍÀ¸·Î º¸°íµÈ´Ù. [»ó¼¼º¸±â]

 



 

µ¨Å¸º¯ÀÌ(B.1.617.2) ÁÖ¿ä Áõ»ó ¹× ±Û·Î¹ú È®»êÇöȲ

(Delta Variant’s Sign & Symptoms)

 

WHO´Â ÃÖ±Ù Äڷγª19 ÇöȲ º¸°í¿¡¼­ ¿ì·ÁµÇ´Â º¯ÀÌ(VOC)ÀÇ Ç¥ÇöÇü Ư¼º(ÀüÆļº, Áúº´½É°¢µµ, Àç°¨¿° À§Çè, Áø´Ü ¹× ¹é½Å È¿´É ¿µÇâ)°ú °ü·ÃµÈ »õ·Î¿î ¾÷µ¥ÀÌÆ®¸¦ ¹ßÇ¥Çß´Ù. ¿©±â¿¡´Â  Äڷγª º¯ÀÌ ¹ÙÀÌ·¯½ºÀÇ Áö¸®Àû ºÐÆ÷¸¦ Æ÷ÇÔÇÏ¿© VOCs ¹× º¯ÀÌ ºÐ·ù, ¸ð´ÏÅ͸µ ÁßÀÎ ¾Æ¹Ì³ë»ê º¯È­ ¹× ±âŸ º¯ÀÌ ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ³»¿ëÀ» ¹ßÇ¥Çß´Ù.  [»ó¼¼º¸±â]






 

Äڷγª19 ¹é½Å È¥ÇÕ-±³Â÷ Á¢Á¾ È¿°ú¿Í ºÎ½ºÅͼ¦?

(Mix-and-Match Approach to Covid Vaccines)

 

-¾Æ½ºÆ®¶óÁ¦³×Ä« & È­ÀÌÀÚ ±³Â÷Á¢Á¾ È¿°ú- 

 

Covid ¹é½Å¿¡ ´ëÇÑ ¹Í½º ¾Ø ¸ÅÄ¡ ¹æ½Ä (1Â÷ ¹× 2Â÷ Á¢Á¾¿¡ ¼­·Î ´Ù¸¥ ºê·£µåÀÇ ¹é½Å »ç¿ë)Àº Äڷγª ÆÒµ¥¹Í ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ È¿°úÀûÀÎ ¿¹¹æÀÌ µÉ ¼ö ÀÖÀ½ÀÌ ¿µ±¹ÀÇ ÇÑ ¿¬±¸¿¡¼­ ¹àÇôÁ³´Ù. Äڷγª19 ¹é½Å È¥ÇÕ-±³Â÷ Á¢Á¾ ¿¬±¸°á°ú(Mix-and-Match Approach to Covid Vaccines) [»ó¼¼º¸±â]




 

“µ¨Å¸ Ç÷¯½º(Delta Plus)” º¯ÀÌ ¹é½ÅÈ¿°ú?

'Delta' Variant Of COVID-19 Mutates Into 'Delta Plus'

 

Àεµ¿¡¼­ óÀ½ ¹ß»ýÇÑ ‘µ¨Å¸’(Delta) º¯ÀÌ ¹ÙÀÌ·¯½ºÀÇ Àü ¼¼°è È®»êÀÌ °Å¼¼Áö°í ÀÖ´Ù.  µ¨Å¸º¯ÀÌ´Â Áö³­ÇØ 10¿ù Àεµ¿¡¼­ óÀ½ º¸°í µÇ¾úÀ¸³ª,  ¿µ±¹¿¡¼­ óÀ½ ¹ß°ßµÈ ‘¾ËÆÄ’( alpha) ¹öÀü°ú ºñ±³ÇÏ¿© 50ÆÛ¼¾Æ® ÀÌ»óÀÇ °­ÇÑ °¨¿°·ÂÀ» ³ªÅ¸³»°í ÀÖ´Ù. ƯÈ÷ µ¨Å¸ º¯ÀÌ ¹ÙÀÌ·¯½º¿Í ºñ±³ÇÏ¸é ‘µ¨Å¸ Ç÷¯½º’ µ¹¿¬º¯ÀÌ´Â ÀüÆÄ·Â »Ó¸¸ ¾Æ´Ï¶ó ¹é½Å¿¡ ´ëÇÑ ³»¼ºÀÌ ´õ °­ÇÑ °ÍÀ¸·Î Æò°¡¹Þ°í ÀÖÀ¸¸ç, ‘µ¨Å¸ Ç÷¯½º º¯ÀÌ’°¡  ÀÌ¹Ì Àεµ 3°³ Áö¿ªÀ» Æ÷ÇÔÇÏ¿© ¹Ì±¹, ¿µ±¹, Áß±¹, ÀϺ»±îÁö °¨¿°ÀÌ È®»êµÇ¾î ¹ß»ýÇÏ°í ÀÖ´Ù.  [»ó¼¼º¸±â]

 

 

¿Á½ºÆ÷µå-¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½Å 3»ó ÀÓ»ó°á°ú(Phase III, Clinical Trial)  ¹ßÇ¥ (Latest results put Oxford–AstraZeneca COVID vaccine back on track)

¿Á½ºÆ÷µå-¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½Å °³¹ß»ç´Â ÃÖ±Ù 3¿ù 26ÀÏÀÚ·Î ÇÙ½ÉÀ̵Ǵ ÀÓ»ó 3»ó(Phase III Clinical Trial) ¿¬±¸°á°ú¿¡¼­ 76%ÀÇ Äڷγª-19¹é½Å ¿¹¹æÈ¿°ú °á°ú¸¦ ¹ßÇ¥Çß´Ù. À¯·´ÀǾàǰû(EMA)Àº ¹é½ÅÀÇ Ç°Áú, ¾ÈÀü¼º ¹× È¿´É¿¡ ´ëÇÑ µ¥ÀÌÅÍ Æò°¡¸¦ ÅëÇØ, 18¼¼ÀÌ»ó ¼ºÀÎÀ» ´ë»óÀ¸·Î ¿Á½ºÆ÷µå-¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½ÅÁ¢Á¾ ½ÂÀÎÀ» Çã¿ëÇÔÀ» ¹ßÇ¥Çß´Ù.  [»ó¼¼º¸±â]

 



 

COVID-19 ¼¼°¡Áö Áø´Ü°Ë»ç ºñ±³ : ºñÀεεµ¸» PCR, Ÿ¾× PCR, ½Å¼ÓÇ׿ø°Ë»ç - Three COVID-19 Diagnostic Tests in Korea -




 

"ºñÀεεµ¸» PCR→Ÿ¾× PCR→½Å¼ÓÇ׿ø°Ë»ç ¼ø ±ÇÀå…°Ë»ç°á°ú Á¤È®µµ Â÷ÀÌ"

 

¿ì¸®³ª¶ó¿¡¼­ ÇöÀç ½ÃÇàµÇ°í ÀÖ´Â ¼¼°¡Áö Äڷγª19 °Ë»çÁø´Ü¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù. Áúº´°ü¸®Ã» Á߾ӹ濪´ëÃ¥º»ºÎ´Â Äڷγª19 Á¤·Êºê¸®Çο¡¼­ ¼¼ °¡Áö Äڷγª19 °Ë»ç¹ý¿¡ ´ëÇØ ¼³¸íÇϸ鼭 ¹Î°¨µµ(Sensitivity)¿Í ƯÀ̵µ(specificity)¸¦ °ø°³Çß´Ù. Ç¥ÁØ°Ë»ç¹ýÀÎ ºñÀεεµ¸» PCR(½Ç½Ã°£ ¿ªÀü»ç ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ, rRT-PCR, qRT-PCR)Àº ¹Î°¨µµ 98% ÀÌ»ó, ƯÀ̵µ 100%À̸ç Ÿ¾× PCRÀº ¹Î°¨µµ 92%, ƯÀ̵µ 100%´Ù.  ¹Ý¸é, ½Å¼ÓÇ׿ø°Ë»ç¹ýÀº ¹Î°¨µµ 90%, ƯÀ̵µ 96%·Î ¼¼ °¡Áö °Ë»ç¹ý Áß °¡Àå ³·´Ù[»ó¼¼º¸±â]





 

³ëÈ­ÀÇ °üÁ¡¿¡¼­ COVID-19 ÀÓ»óÀû ¾ç»ó - COVID-19 ³ëÀΠȯÀÚÀÇ ³ôÀº ¿°Áõ»óÅ ¹× ³·Àº ¸é¿ª¹æ¾î´É·Â 



 

Understanding the Clinical Features of Coronavirus Disease 2019 From the Perspective of Aging: A Systematic Review and Meta-Analysis

 

-High Inflammatory State and Low Immune Defense of the Aging Patients With COVID-19-




 

ÀÓ»óÁú¹® : 

³ëÀε鿡°Ô Äڷγª19 °¨¿°ÀÌ ´õ¿í À§Çè°ÍÀº ÀþÀº Ãþ¿¡ ºñÇÏ¿©  ³·Àº ¸é¿ª¹æ¾î ´É·ÂÀ̳ª ³ôÀº ¿°Áõ»óÅÂ¿Í °ü·ÃÀÌ ÀÖ½À´Ï±î? 

 

¿¬±¸´äº¯ :

³ëÀÎÃþ ȯÀÚÀÇ Ç÷¾×°Ë»ç°á°ú ÀþÀº Ãþ¿¡ ºñÇÏ¿© ¹éÇ÷±¸ÀÇ ³ôÀº °¡º¯¼ºÀ» ³ªÅ¸³»¾ú´Ù. COVID-19 ³ëÀÎȯÀÚÀÇ ½ÇÇè½Ç °á°ú ³ôÀº ¿°Áõ»óÅ ¹× ³·Àº ¸é¿ª¹æ¾î´É·ÂÀ¸·Î COVID-19 ³ëÀÎ Àα¸¿¡¼­ COVID-19·Î ÀÎÇÑ Ãë¾à¼º°ú ºÒ¾ÈÁ¤ÇÑ »óŸ¦ ³ªÅ¸³»¾ú´Ù. Ç÷¾×°Ë»ç °á°ú  C- ¹ÝÀÀ¼º ´Ü¹éÁú, ÇÁ·Î Ä®½ÃÅä´Ñ ¹× ÀÎÅÍ·çŲ -6 (C-reactive protein, procalcitonin, and interleukin-6)  Åë°è ºÐ¼®À» ¼öÇàÇÏ¿© ³ëÀΠȯÀÚÀÇ ¿°Áõ ¹× ¸é¿ª ¹ÝÀÀÀ» Ãß·ÐÇÏ°í Ç÷¼ÒÆÇ°ú D-dimer¸¦ °è»êÇÏ¿© ³ëÀΠȯÀÚÀÇ ÀÀ°í±â´ÉÀ» È®ÀÎÇÏ¿´´Ù[»ó¼¼º¸±â]




 

[NEJM] È­ÀÌÀÚ & ¹ÙÀÌ¿À¿£Å×Å© COVID-19 ¹é½Å(Pfizer-BioNTech  BNT162b2 mRNA COVID-19 Vaccine) ÀÓ»ó°á°ú ¹× ºÎÀÛ¿ë ¹ßÇ¥

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine



 



 

¹Ì±¹ Á¦¾àȸ»ç È­ÀÌÀÚ¿Í µ¶ÀÏ »ý¸í°øÇбâ¾÷ ¹ÙÀÌ¿À¿£Å×Å©(BioNTech SE)´Â mRNA ±â¹Ý Äڷγª19 ¹é½Å Èĺ¸¹°Áú ‘BNT162b2’ÀÇ ÀÓ»ó 3»ó ½ÃÇè¿¡¼­ µµÃâµÈ ¾ÈÀü¼º ¹× È¿´É¼º °á°ú¿¡ ´ëÇØ ÀÇÇÐ ÇмúÁö ‘´º À×±Û·£µå Àú³Î ¿Àºê ¸Þµð½¼’(NEJM)¿¡ °ÔÀçµÆ´Ù°í 10ÀÏÀÚ·Î ¹ßÇ¥Çß´Ù[»ó¼¼º¸±â].






 

COVID-19 ȯÀÚÀÇ Ä¡¸íÀ², ÀÓ»óƯ¼º, Åð¿øÀ²  

COVID?19 patients' clinical characteristics, discharge rate, and fatality rate of meta?analysis

ÀÌ ¿¬±¸´Â COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î COVID-10ȯÀÚÀÇ Åð¿ø·ü ¹× »ç¸Á·üÀ» ºÐ¼®ÇϱâÀ§ÇØ 2019 ³â 12 ¿ùºÎÅÍ 2020 ³â 2 ¿ù±îÁö COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅÍ´Â 4 °³ÀÇ µ¥ÀÌÅͺ£À̽º¿¡¼­ °Ë»öÇÏ¿´´Ù. COVID-19 ȯÀÚÀÇ ÀÓ»ó Áõ»ó°ú °Ë»ç½Ç °á°ú¸¦ Åë°èÀûÀ¸·Î ºÐ¼®ÇÏ°í ´ÜÀÏ ±º ¸ÞŸ ºÐ¼®À¸·Î Åð¿øÀ² °ú »ç¸Á·üÀ» ¼³¸íÇß´Ù. 10°³ÀÇ ¹®Çå¿¡¼­ 1994 ³â ȯÀÚÀÇ ÀÌ¿ë °¡´ÉÇÑ µ¥ÀÌÅÍ°¡ ¿¬±¸¿¡ Æ÷ÇԵǾú´Ù. [»ó¼¼º¸±â]

 

 

Source: Johns Hopkins University CSSE COVID 19 Data-Last Updated 8 December, 21:06 (London time) 

 

 

[JAMA]  COVID-19 °¨¿°µÈ »ê¸ð¿¡¼­ ž ½Å»ý¾Æ´Â COVID-19 Ç×üº¸À¯ (Antibodies in Infants Born to Mothers With COVID-19 Pneumonia)

 

JAMA¿¡ ¹ßÇ¥µÈ À̹ø ¿¬±¸´Â COVID-19°¡ È®Áø µÈ 6 ¸íÀÇ ÀÓ»êºÎ¿Í  ½Å»ý¾Æ¿¡°Ô »õ·Î¿î Ç÷ûÇÐÀû ±âÁØÀ¸·Î ½Å»ý¾Æ °¨¿°¿¡ ´ëÇÑ º¸´Ù ÀÚ¼¼ÇÑ Á¶»ç ±âÁØÀ» Àû¿ëÇؼ­ COVID-19¿¡ °¨¿°µÈ ¸ð¼º¿¡°Ô¼­ ž ½Å»ý¾ÆÀÇ COVID-19 Ç×ü º¸À¯¿¡ ´ëÇÑ ¿¬±¸¸¦ ¼öÇàÇÏ¿´´Ù. [»ó¼¼º¸±â]



 

COVID-19 Vaccines ºñ±³: È­ÀÌÀÚ(Pfizer & BioNTech), ¸ð´õ³ª(Moderna) & ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca) 

 



 

¹Ì±¹ È­ÀÌÀÚ¿Í µ¶ÀÎ ¹ÙÀÌ¿À¿£Å×Å©(Pfizer & BioNTech) °³¹ßÇÑ COVID-19 ¹é½Å°ú ¹Ì±¹ ¸ð´õ³ª(Moderna) Á¦¾àȸ»çÀÇ ¹é½Å °³¹ß ¹ßÇ¥¿¡ À̾î, ¿µ±¹°è ´Ù±¹Àû Á¦¾à»ç ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca)´Â 23ÀÏ Èıâ ÀÓ»ó½ÃÇè¿¡¼­ 90% È¿°ú°¡ ÀÖ´Â °­·ÂÇÑ COVID-19 ¹é½ÅÀÇ ÀÓ»ó½ÃÇè °á°ú¸¦ ÀÕ´Þ¾Æ ¹ßÇ¥Çß´Ù. ÀÌÁ¦ Àü¼¼°è´Â Äڷγª19 °¨¿°À» µåµð¾î ³¡³¾ ¹é½ÅÀÌ °³¹ßµÈ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ´Ù. [»ó¼¼º¸±â]

 

NIH- Remdesivir (·½µ¥½Ãºñ¸£) COVID-19 Ä¡·áÁ¦·Î ½ÂÀÎ



 

¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¿ø(NIH)ÀÌ ¼öÇàÇÑ Ç×¹ÙÀÌ·¯½º ·½µ¥½Ãºñ¾î(remdesivir) ÀÓ»ó½ÃÇ迬±¸ °á°ú°¡ NEJM (New England Journal of Medicine.)À» ÅëÇØ ¹ßÇ¥µÇ¾ú´Ù. (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home)

ÀÌ °á°ú¸¦ ±Ù°Å·Î 5¿ù 1ÀÏ¿¡ ¹Ì±¹ FDA(½Ä¾àó)´Â ·½µ¥½Ãºñ¾î¸¦ ¡¸ÁßÁõ¡¹È¯ÀÚ(»ê¼ÒÆ÷È­µµ <94%, »ê¼Ò Ä¡·á ÇÊ¿ä)¿¡°Ô ±ä±Þ»ç¿ëÇã°¡¸¦ ½ÂÀÎÇÏ¿´À¸¸ç, ÀÌÁ¦ ·½µ¥½Ãºñ¾î°¡ COVID-19ÀÇ Ç¥ÁØ Ä¡·áÁ¦·Î »ç¿ëÇã°¡µÇ¾ú´Ù. [»ó¼¼º¸±â]




 

[±¹³»Ç÷ÀåÄ¡·á¼º°ø] COVID-19: ¿ÏÄ¡ÀÚ Ç÷ÀåÄ¡·á(Convalescent Plasma) 

±¹³» ¼¼ºê¶õ½ºº´¿ø ¿¬±¸ÆÀÀº ¿ÏÄ¡ÀÚ Ç÷Àå(Convalescent Plasma) Ä¡·á¹æ¹ýÀ¸·Î ÀÓ»ó¿¡¼­ Coronavirus disease 2019 (COVID-19)ÀÇ ¿ÏÄ¡ »ç·Ê¸¦ º¸°íÇß´Ù. ÀÌ°ÍÀº Çѱ¹¿¡¼­ COVID-19¿¡ ´ëÇÑ ¿ÏÄ¡ÀÚ Ç÷Àå Ä¡·á¿¡ ´ëÇÑ Ã¹ ¹ø° ÀÓ»ó ¿ÏÄ¡»ç·ÊÀÌ´Ù. [»ó¼¼º¸±â]



 

COVID-19 Ä¡·áÁ¦°³¹ß ±Û·Î¹ú Àӻ󿬱¸ ÇÁ·ÎÁ§Æ®ÇöȲ

½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ Àü¼¼°è°¡ ³ë·ÂÇÏ°í ÀÖ´Â °¡¿îµ¥, ÇöÀç Äڷγª 19 Ä¡·áÁ¦ °³¹ß°ú °ü·Ã ±¹Á¦ÀûÀ¸·Î Àӻ󿬱¸°¡ 335,815°ÇÀÌ ÁøÇà Áß¿¡ ÀÖ´Ù(2020³â 4¿ù 13ÀÏÀÚ µî·ÏÇöȲ). ¹Ì±¹ ±¹¸³º¸°Ç¿ø NIH ClinicalTrials.gov¿¡ µî·ÏµÇ¾î ÁøÇàÇÏ°í ÀÖ´Â COVID-19 °ü·Ã Àӻ󿬱¸´Â 300¿©°Ç ÀÌ»óÀÌ ÁøÇà Áß¿¡ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)±¹Á¦Àӻ󿬱¸µî·Ï Ç÷§Æû(World Health Organization's International Clinical Trials Registry Platform, WHO ICTRP)¿¡¼­´Â 590°ÇÀÇ ÇÁ·ÎÁ§Æ®°¡ ÇöÀç Àӻ󿬱¸ Áß¿¡ ÀÖ´Ù.  [»ó¼¼º¸±â]



 

NEJM COVID-19 º¸°í [½ÉÇ÷°üÁúȯ ¾à¹°Ä¡·á, »ç¸Á·ü ¿äÀÎ ¿¬±¸(Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19): Angiotensin-converting–enzyme (ACE) inhibitors & angiotensin-receptor blockers (ARBs)]

 

º» ¿¬±¸´Â The New England Journal of Medicine 2020³â 5¿ù 1ÀÏÀÚ ¹ßÇ¥µÈ COVID-19 ½ÉÇ÷°üÁúȯÀÇ ¾à¹°Ä¡·á-  Angiotensin-converting–enzyme (ACE) inhibitors¿Í Angiotensin-receptor blockers (ARBs) »ç¿ë¿¡ ´ëÇÑ ÀáÀçÀû À§Çؼº Æò°¡¿Í »ç¸Á·ü °ü·Ã¿äÀÎ ¿¬±¸ÀÌ´Ù. 

 

º´¿ø ³» »ç¸ÁÀ² Áõ°¡¿Í °ü·ÃÀÖ´Â µ¶¸³¿äÀεéÀº ¾Æ·¡¿Í °°´Ù.

 

1. 65¼¼ ÀÌ»ó ¿¬·É( (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41) (65 ¼¼ ¹Ì¸¸ÀÇ »ç¸Á·üÀº 10.0 %, »ç¸Á·üÀº 4.9 %)

2. °ü»óµ¿¸Æ Áúȯ(10.2%, vs. 5.2% among those without disease; OR, 2.70; 95% CI, 2.08 to 3.51)

3. ½ÉºÎÀü(15.3%, vs. 5.6% among those without heart failure; OR 2.48; 95% CI, 1.62 to 3.79) 

4. ½ÉÀåºÎÁ¤¸Æ(11.5%, vs. 5.6% among those without arrhythmia; OR, 1.95; 95% CI, 1.33 to 2.86)

5. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(14.2%, vs. 5.6% among those without disease; OR, 2.96; 95% CI, 2.00 to 4.40) 

6. ÇöÀç Èí¿¬(9.4%, vs. 5.6% among former smokers or nonsmokers; OR, 1.79; 95% CI, 1.29 to 2.47)

¾à¹°Ä¡·á¿Í »ç¸Á·ü°úÀÇ °ü·ÃÀ» ºÐ¼®ÇÑ °á°ú, ACE inhibitors (2.1% vs. 6.1%; OR, 0.33; 95% CI, 0.20 to 0.54) »ç¿ëÀ̳ª, ARB(6.8% vs. 5.7%; OR, 1.23; 95% CI, 0.87 to 1.74) ¾à¹°Ä¡·á´Â º´¿ø³»¿¡¼­ »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃÅ°´Â °Í°ú °ü·ÃÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. [¿ø¹®º¸±â]

 

COVID-19: ÁßÁõ ¼ºÀÎȯÀÚ ICU ÆÐÇ÷Áõ °¡À̵å¶óÀÎ

ÁßÁõ±Þ¼ºÈ£Èí±âÁõÈıºÀ» ¾ß±âÇÏ´Â SARS-CoV-2´Â Àü¼¼°èÀûÀ¸·Î ±Þ¼ÓÇÏ°Ô È®»êµÇ°í ÀÖÀ¸¸ç ¼ö¸¹Àº »ç¶÷µéÀÇ »ý¸íÀ» À§ÇùÇÏ°í ÀÖ´Ù. À̵éÀ» µ¹º¸´Â º¸°ÇÀÇ·áÀεé°ú ÀÓ»óÀǻ縦 À§ÇÑ ±ä±ÞÇÑ °¡À̵å¶óÀÎ °³¹ßÀÌ ÇÊ¿äÇÏ´Ù. COVID-19·Î ÀÎÇÑ ÆÐÇ÷Áõ °ü¸® ÁöħÀ» À§ÇØ ±¸¼ºµÈ ÆгÎÀº 54°³ÀÇ Áø¼ú¹®À» ¸¸µé¾ú°í ÀÌÁß¿¡¼­ 4°¡Áö º£½ºÆ® ½Ç¹«°¡À̵å¶óÀΰú 9°¡Áö °­·ÂÇÑ ±Ç°í»çÇ×°ú, 35°¡Áö Áõ°Å°¡ ºÎÁ·ÇÑ Á¦¾ÈµéÀº ¹ßÇ¥Çß´Ù. [´õº¸±â]

 


 

Ç¥ 5) Coronavirus disease (COVID-19) ±¹³» ¹× ±¹¿Ü COVID -19 ÃֽŠÁ¤º¸ ¹Ù·Î°¡±â

±¹³» ¹× ±¹¿Ü  ±â°ü

¸µ Å©

Áúº´°ü¸®Ã»  Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ

https://kdca.go.kr/index.es?sid=a2

¹Ì±¹ CDC Coronavirus Disease (COVID-19)

https://www.cdc.gov/coronavirus/index.html

¼¼°èº¸°Ç±â±¸(WHO) Coronavirus (COVID-19) Epidemical Update

https://www.who.int/health-topics/coronavirus#tab=tab_1




 

Ç¥ 6)  Coronavirus disease (COVID-19) ÃֽŠÇмúÁ¤º¸ »çÀÌÆ® ¹Ù·Î°¡±â  

±¹¿Ü ÃֽŠÇмúÁ¤º¸

»çÀÌÆ®

JAMA

https://jamanetwork.com/journals/jama/pages/coronavirus-alert

The Lancet

https://www.thelancet.com/coronavirus

NEJM

https://www.nejm.org/coronavirus

Cambridge University Press

https://www.cambridge.org/core/browse-subjects/medicine/coronavirus-free-access-collection#

Centers for Disease Control and Prevention

https://www.cdc.gov/coronavirus/index.html

WHO 

https://www.who.int/westernpacific/emergencies/novel-coronavirus

Elsevier

https://www.elsevier.com/connect/coronavirus-information-center

Cochrane

https://www.cochranelibrary.com/collections/doi/SC000039/full

Karger

https://www.karger.com/Tap/Home/278492

Oxford University Press

https://global.oup.com/academic/category/medicine-and-health/coronavirus/?cc=us&lang=en&A

Science

https://www.sciencemag.org/tags/coronavirus

Springer

https://www.springernature.com/gp/researchers/campaigns/coronavirus

Wiley Library

https://novel-coronavirus.onlinelibrary.wiley.com/

Wolters Kluwer

http://healthclarity.wolterskluwer.com/coronavirus-resources.html

The Scientist

https://www.the-scientist.com/tag/coronavirus

Taylor & Francis Group

https://newsroom.taylorandfrancisgroup.com/coronavirus-reading-list/#







 




 

      ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC) Á¦°ø



 

* º» ³»¿ëÀº MedRIC (www.medric.or.kr)ÀÇ ¿¬±¸µ¿Çâ¿¡¼­ ¼­ºñ½ºµÇ´Â ³»¿ëÀÔ´Ï´Ù.

 

 


2021-08-06 ¿ÀÀü 11:59:22, Á¶È¸¼ö : 3077